What topics does this cannabis study cover?

This study covers research on: CBD, Pain, Inflammation, Terpenes, Endocannabinoid.

CBD Pain Inflammation Terpenes Endocannabinoid

Systematic review finds CBD–BCP pain effects only in rodents

Q: What did this research study find?

The review included **5 studies**, all using *rodent models*, and found that combining *CBD* with *beta-caryophyllene (BCP)* consistently reduced neuropathic and inflammatory pain.

Q: Where was this research published?

Published in Phytomedicine : international journal of phytotherapy and phytopharmacology on September 11, 2026.

Exploring the potential benefits of combining cannabidiol and beta-caryophyllene for neuropathic and inflammatory pain: A systematic review.

Phytomedicine : international journal of phytotherapy and phytopharmacology • September 11, 2026 • Highly Relevant

🤖

AI Summary

This systematic review examined whether combining cannabidiol (CBD) with beta-caryophyllene (BCP) could reduce neuropathic and inflammatory pain. Searches of major academic databases identified 31 records; 10 reports were screened, and 5 studies met the review criteria. The included research was conducted in rodent models, not human participants, and assessed the pain-relieving effects of the CBD–BCP combination.

Across the included studies, the combination consistently reduced neuropathic and inflammatory pain in rodents. The review also reports no adverse outcomes associated with cannabinoid receptor 1 (CB1) in these models and discusses possible synergistic mechanisms. However, this abstract does not provide quantitative effect sizes or establish whether the findings translate to people; as an abstract-based summary, its most consequential limitation is that the evidence is limited to a small set of preclinical studies and requires further preclinical and clinical investigation.

💡 Key Findings

The review included 5 studies, all using rodent models, and found that combining CBD with beta-caryophyllene (BCP) consistently reduced neuropathic and inflammatory pain.

High

80%

The reported pain reduction was not accompanied by adverse outcomes associated with cannabinoid receptor 1 (CB1) in the rodent studies.

Good

70%

The findings support a possible synergistic effect between CBD and BCP, but the review provides no quantitative effect sizes and cannot establish efficacy or safety in humans.

High

95%

📄 Original Abstract

PURPOSE: In this review, we examined the analgesic effect of the combination of cannabidiol (CBD) and beta-caryophyllene (BCP) in different pain conditions. METHODS: A systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Literature searches were performed across major academic databases (Google Scholar, Web of Science, and PubMed) from 2009 to 2026 to identify studies investigating the analgesic effect of the combination of CBD and BCP. RESULTS: The search identified 31 records. Ten reports were screened and assessed for eligibility, and five studies met the inclusion and exclusion criteria. Findings consistently demonstrate that the combination of CBD and BCP reduces neuropathic and inflammatory pain in rodent models. This effect does not result in adverse outcomes associated with cannabinoid receptor 1 (CB1). This review discusses potential mechanisms by which this combination produces synergistic analgesic effects. CONCLUSION: The literature discussed in this review suggests that the combination of CBD and BCP can work in synergy in chronic pain without cannabinoid receptor 1 central side effects. These preclinical findings provide the rationale for future preclinical and clinical studies.